Hilleman Labs, NICED to develop Shigella Vaccine

The two aim to complete the development of this vaccine by 2024, according to Hilleman Labs chief executive officer Davinder Gill.
Source: The Economic Times - Category: Consumer Health News Source Type: news

Related Links:

The Journal of Physical Chemistry BDOI: 10.1021/acs.jpcb.0c01595
Source: Journal of Physical Chemistry B - Category: Chemistry Authors: Source Type: research
This study contributes to a better understanding of growth, survival, and disease mechanism at molecular level and provides potential new targets for designing drugs against Shigella infection.
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
Conditions:   Diarrhea;   Diarrhea Infectious Intervention:   Other: no intervention Sponsors:   Centre for Infectious Disease Research in Zambia;   European Vaccine Initiative;   Groupe de Recherche Action en Sante Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: May 2020Source: Molecular Immunology, Volume 121Author(s): Yrvin León, Lionel Zapata, Alexis Salas-Burgos, Angel Oñate
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 17 February 2020Source: International Journal of PharmaceuticsAuthor(s): Yadira Pastor, Isaiah Ting, Ana Luisa Martínez, Juan Manuel Irache, Carlos GamazoAbstractThermosensitive hydrogels have been studied as feasible needle-avoidance alternative to vaccine delivery. In this work, we report the development of a new thermal-sensitive hydrogel for intranasal vaccine delivery. This delivery system was formulated with a combination of the polymer Gantrez® AN119 and the surfactant Pluronic® F127 (PF127), with a high biocompatibility, biodegradability and immunoadjuvant propertie...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Abstract Vaccine implementation planning in low- and middle-income countries (LMIC) often focuses on children without considering special adult populations. We adapted an economic model developed by the United States Department of Defense (DoD) to evaluate the cost-effectiveness of vaccine acquisition strategies for Campylobacter-, ETEC-, Shigella-, and norovirus-associated gastroenteritis. We compared implementation costs with current medical management in the Peruvian armed forces, a special population of low- and middle-income (LMIC) adults with a high incidence of infectious gastroenteritis. Pathogen-specific ...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Conditions:   Immunisation;   Shigella Infection Interventions:   Other: Placebo;   Biological: Shigella sonnei strain 53G;   Biological: WRSs2 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Dysentery | Gastroenteritis | Health | Vaccines